OFD 2025: Myeloma 101 – The Basics

Multiple Myeloma is the third-most common hematological cancer in Canada behind non-Hodgkin’s lymphoma and leukemia. This presentation aims to provide a solid foundational understanding of this disease, tailored to new oncology pharmacy practitioners or general pharmacy practitioners who care for cancer patients. The initial focus will centre on the background (incidence, mortality, risk factors), pathophysiology/clinical presentation, diagnosis and relevant tests. We will then examine the current treatment options available for multiple myeloma by familiarizing ourselves with the various pharmacotherapy classes of medications and how these agents fit into the current Canadian landscape for treatment. Lastly, we'll take a brief look at supportive care strategies that are utilized in this population.

Learning Objectives
By the end of the session participants will be able to:

1. Describe the incidence, mortality, and risk factors of Multiple Myeloma (MM)
2. Understand the pathophysiology of MM, including clinical presentation, diagnosis and relevant tests
3. Summarize the current treatment options for MM
4. Become familiar with the various drug classes used in MM treatment, including mechanisms of action, dosing, adverse effects, and common drug interactions
5. Describe supportive care strategies including bone modifying agents and antimicrobial prophylaxis in MM